Skip to Content

Paradione (paramethadione) Disease Interactions

There are 8 disease interactions with Paradione (paramethadione):

Major

Oxazolidinediones (Includes Paradione) ↔ Blood Dyscrasias

Severe Potential Hazard, High plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

Hematologic toxicities have been associated with the use of oxazolidinedione anticonvulsants. Fatal aplastic anemia, hypoplastic anemia, pancytopenia, agranulocytosis, leukopenia, neutropenia, thrombocytopenia, eosinophilia, retinal and petechial hemorrhages, vaginal bleeding, epistaxis, and bleeding gums have been reported. Therapy with oxazolidinediones should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression. Complete blood counts, including platelets, should be performed in all patients prior to initiating therapy and at monthly intervals, or as often as necessary, thereafter. A moderate degree of neutropenia, with or without a corresponding drop in the leukocyte count, is not uncommon and does not necessitate the discontinuation of therapy. However, more frequent monitoring is recommended if neutrophil count is less than 3000/mm3. Marked depression of blood counts (e.g., neutrophil count < 2500/mm3) is indication for withdrawal of oxazolidinedione therapy.

References

  1. "Product Information. Paradione (paramethadione)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Tridione (trimethadione)" Abbott Pharmaceutical, Abbott Part, IL.
Major

Oxazolidinediones (Includes Paradione) ↔ Hemeralopia

Severe Potential Hazard, High plausibility

Applies to: Retinal Disorder, Optic Nerve Disorder

Hemeralopia has occurred with the use of oxazolidinedione anticonvulsants, probably as a result of the drugs' effects on the neural layers of the retina. The condition may be reversed by a reduction in dosage. Therapy with oxazolidinediones should be administered cautiously in patients with diseases of the retina or optic nerve. The development of scotomata or other significant ocular abnormality is indication for withdrawal of oxazolidinedione therapy.

References

  1. "Product Information. Paradione (paramethadione)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Tridione (trimethadione)" Abbott Pharmaceutical, Abbott Part, IL.
Major

Oxazolidinediones (Includes Paradione) ↔ Liver Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Hepatitis has been associated rarely with the use of oxazolidinedione anticonvulsants. In addition, these agents are primarily metabolized by the liver and may accumulate in the presence of liver disease. Therapy with oxazolidinediones should be administered cautiously, if at all, in patients with hepatic impairment. Liver function tests should be performed in all patients prior to initiating therapy and at monthly intervals, or as often as necessary, thereafter. The development of jaundice or other signs of liver dysfunction is indication for withdrawal of oxazolidinedione therapy.

References

  1. "Product Information. Paradione (paramethadione)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Tridione (trimethadione)" Abbott Pharmaceutical, Abbott Part, IL.
Major

Oxazolidinediones (Includes Paradione) ↔ Rash

Severe Potential Hazard, High plausibility

Applies to: Dermatitis - Drug-Induced

Potentially serious reactions to oxazolidinedione anticonvulsants such as exfoliative dermatitis and severe forms of erythema multiforme have been reported. Therapy with oxazolidinediones should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to oxazolidinediones. Oxazolidinedione therapy should be withdrawn promptly at the first sign of a dermatologic adverse effect. Even a minor acneiform or morbilliform rash should be allowed to clear completely before treatment with these agents is resumed.

References

  1. "Product Information. Tridione (trimethadione)" Abbott Pharmaceutical, Abbott Part, IL.
  2. "Product Information. Paradione (paramethadione)." Abbott Pharmaceutical, Abbott Park, IL.
Major

Oxazolidinediones (Includes Paradione) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Fatal nephrosis has been associated with the use of oxazolidinedione anticonvulsants. In addition, the active metabolites of these agents are excreted slowly by the kidney and may accumulate in the presence of renal disease. Therapy with oxazolidinediones should be administered cautiously, if at all, in patients with impaired renal function. Urinalyses should be performed in all patients prior to initiating therapy and at monthly intervals, or as often as necessary, thereafter. The development of persistent or increasing albuminuria or any other significant renal abnormality is indication for withdrawal of oxazolidinedione therapy.

References

  1. "Product Information. Tridione (trimethadione)" Abbott Pharmaceutical, Abbott Part, IL.
  2. "Product Information. Paradione (paramethadione)." Abbott Pharmaceutical, Abbott Park, IL.
Moderate

Antiepileptics (Includes Paradione) ↔ Suicidal Tendency

Moderate Potential Hazard, Moderate plausibility

Applies to: Depression, Psychosis

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs across multiple indications in either monotherapy or adjunctive therapy for a median treatment duration of 12 weeks (up to a maximum of 24 weeks) showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. The estimated rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% for 16,029 placebo-treated patients, representing an increase of approximately one case for every 530 patients treated. There were four suicides in AED-treated patients and none in placebo-treated patients, although the number is too small to establish any causal relationship. The increased risk of suicidal thoughts or behavior was observed as early as one week after starting AEDs and persisted for the duration of treatment assessed. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed. Therapy with AEDs should be administered cautiously in patients with depression or other psychiatric disorders. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. For clinically significant or persistent symptoms, a dosage reduction or treatment withdrawal should be considered. If patients have symptoms of suicidal ideation or behavior, treatment should be discontinued.

Moderate

Oxazolidinediones (Includes Paradione) ↔ Myasthenia Gravis

Moderate Potential Hazard, Moderate plausibility

Applies to: Myasthenia Gravis

A myasthenia gravis-like syndrome has been associated with the chronic use of oxazolidinedione anticonvulsants. Therapy with oxazolidinediones should be administered cautiously in patients with myasthenia gravis. The development or exacerbation of myasthenic symptoms is indication for withdrawal of oxazolidinedione therapy.

References

  1. "Product Information. Paradione (paramethadione)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Tridione (trimethadione)" Abbott Pharmaceutical, Abbott Part, IL.
Moderate

Oxazolidinediones (Includes Paradione) ↔ Sle

Moderate Potential Hazard, Moderate plausibility

Applies to: Lupus Erythematosus

Manifestations of systemic lupus erythematosus (SLE) have been associated with the use of oxazolidinedione anticonvulsants. Therapy with oxazolidinediones should be administered cautiously in patients with preexisting SLE. The development or exacerbation of SLE symptoms is indication for withdrawal of oxazolidinedione therapy.

References

  1. "Product Information. Tridione (trimethadione)" Abbott Pharmaceutical, Abbott Part, IL.
  2. Beernink DH, Miller JJ 3d "Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children." J Pediatr 82 (1973): 113-7
  3. "Product Information. Paradione (paramethadione)." Abbott Pharmaceutical, Abbott Park, IL.

Paradione (paramethadione) drug Interactions

There are 522 drug interactions with Paradione (paramethadione)

Paradione (paramethadione) alcohol/food Interactions

There is 1 alcohol/food interaction with Paradione (paramethadione)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide